UK Markets closed

Celyad SA (CYAD)

NasdaqGM - NasdaqGM Real-time price. Currency in USD
Add to watchlist
4.3300+0.0600 (+1.41%)
At close: 4:00PM EDT
Full screen
Trade prices are not sourced from all markets
Previous close4.2700
Open4.2800
Bid4.2400 x 1000
Ask4.5400 x 1300
Day's range4.2800 - 4.3400
52-week range3.7600 - 10.3100
Volume5,920
Avg. volume25,725
Market cap66.937M
Beta (5Y monthly)1.49
PE ratio (TTM)N/A
EPS (TTM)-1.4880
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est17.47
  • Globe Newswire

    Celyad Oncology Announces September 2021 Conferences Schedule

    MONT-SAINT-GUIBERT, Belgium, Sept. 01, 2021 (GLOBE NEWSWIRE) -- Celyad Oncology SA (Euronext & Nasdaq: CYAD), a clinical-stage biotechnology company focused on the discovery and development of chimeric antigen receptor T cell (CAR T) therapies for cancer, today announced that the Company plans to participate at the following conferences in September 2021: 2021 Wells Fargo Virtual Healthcare ConferenceDates: Thursday, September 9 – Friday, September 10, 2021Presentation date: Thursday, September

  • Globe Newswire

    Celyad Oncology Reports First Half 2021 Financial Results and Recent Business Highlights

    •Enrollment continues at dose level three in Phase 1 IMMUNICY-1 trial evaluating CYAD-211 in relapsed/refractory multiple myeloma (r/r MM); next clinical update expected by year-end 2021 •Phase 1b KEYNOTE-B79 trial set to evaluate CYAD-101 with KEYTRUDA® in metastatic colorectal cancer (mCRC) patients with microsatellite stable disease on-track to begin in the fourth quarter of 2021 •IND-enabling studies in progress for first-in-class shRNA-based allogeneic, IL-18-armored CAR T candidate CYAD-20

  • Globe Newswire

    Information on the Total Number of Voting Rights and Shares (Article 15 of the Law of 2 May 2007)

    MONT-SAINT-GUIBERT, Belgium, July 30, 2021 (GLOBE NEWSWIRE) -- Celyad Oncology SA (Euronext & Nasdaq: CYAD), a clinical-stage biotechnology company focused on the discovery and development of chimeric antigen receptor T cell (CAR T) therapies for cancer, announced on July 30, 2021, a capital increase of 300,000 new shares of the Company to Lincoln Park Capital Fund, LLC (“LPC”), a Chicago-based institutional investor. As a result, the Company’s share capital is increased to 54,956,224.33 EUR and